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Regulation of Chemokine  
Activity – A Focus on the Role 
of Dipeptidyl Peptidase iv/CD26
Mieke Metzemaekers, Jo Van Damme, Anneleen Mortier and Paul Proost*
Laboratory of Molecular Immunology, Department of Microbiology and Immunology, Rega Institute, KU Leuven, Leuven, Belgium
Chemokines are small, chemotactic proteins that play a crucial role in leukocyte migration 
and are, therefore, essential for proper functioning of the immune system. Chemokines 
exert their chemotactic effect by activation of chemokine receptors, which are G 
protein-coupled receptors (GPCRs), and interaction with glycosaminoglycans (GAGs). 
Furthermore, the exact chemokine function is modulated at the level of posttranslational 
modifications. Among the different types of posttranslational modifications that were 
found to occur in  vitro and in  vivo, i.e., proteolysis, citrullination, glycosylation, and 
nitration, NH2-terminal proteolysis of chemokines has been described most intensively. 
Since the NH2-terminal chemokine domain mediates receptor interaction, NH2-terminal 
modification by limited proteolysis or amino acid side chain modification can drastically 
affect their biological activity. An enzyme that has been shown to provoke NH2-terminal 
proteolysis of various chemokines is dipeptidyl peptidase IV or CD26. This multifunctional 
protein is a serine protease that preferably cleaves dipeptides from the NH2-terminal 
region of peptides and proteins with a proline or alanine residue in the penultimate 
position. Various chemokines possess such a proline or alanine residue, and CD26-
truncated forms of these chemokines have been identified in cell culture supernatant 
as well as in body fluids. The effects of CD26-mediated proteolysis in the context of 
chemokines turned out to be highly complex. Depending on the chemokine ligand, loss 
of these two NH2-terminal amino acids can result in either an increased or a decreased 
biological activity, enhanced receptor specificity, inactivation of the chemokine ligand, 
or generation of receptor antagonists. Since chemokines direct leukocyte migration 
in homeostatic as well as pathophysiologic conditions, CD26-mediated proteolytic 
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iNTRODUCTiON
Mammalia are exposed to a variety of pathological agents on a 
daily basis and disease-causing microorganisms such as bacteria 
and viruses are omnipresent. Furthermore, cells of the own body 
can acquire malignant potencies, which make them dangerous 
with respect to the normal physiology. Since the body is equipped 
with a protective system, confrontation with pathological stimuli 
not necessary results in disease. The immune system holds a 
non-specific, innate component that constitutively monitors 
one’s health (1, 2). The process of phagocytosis plays a central 
role in this innate immune system. Phagocytosis by non-specific 
cells such as macrophages induces the clearance of bacteria (3). 
Meanwhile, virally infected cells are attacked by natural killer 
(NK) cells and viral spread is inhibited by interferons (IFNs) (4). 
The second component of the immune system is adaptive and 
requires prior activation and B- and T cell proliferation (5–9). 
As a consequence, the adaptive immune system generates only 
a slow response upon contact with a particular microorganism 
for the first time. However, adaptive immunity is characterized 
by memory, which enables fast induction of a highly specific 
response when the organism is exposed to the same pathogen 
in the future (5, 6). In general, the adaptive immune system is 
subdivided into humoral and cellular immunity, with B and 
T  lymphocytes being the most important effector cells, respec-
tively. Helper T lymphocytes stimulate B lymphocytes to produce 
antibodies against epitopes that are foreign to the body. The 
capacity to produce antibodies makes the B lymphocytes impor-
tant players in immune defense against extracellular pathogens. 
In addition, cytotoxic and helper T lymphocytes are responsible 
for combatting intracellular microorganisms (7, 8). Furthermore, 
regulatory T lymphocytes are crucial for maintaining tolerance to 
commensal microflora (9).
Leukocytes are crucial for correct functioning of host protec-
tion. Different leukocytes, i.e., neutrophils, eosinophils, basophils, 
lymphocytes, NK cells, monocytes, macrophages, and dendritic 
cells, have subtype-specific shapes and functions. Obviously, the 
presence of the correct cells on the right place at the right time is 
essential to allow the desired interactions between the different 
leukocyte subtypes and between leukocytes and pathogens result-
ing in proper functioning of the immune system (10–12). On the 
one hand, hyperactivation of the immune system can result in 
allergic or autoimmune responses. On the other hand, immune 
incompetence has been associated with a significantly increased 
risk of developing disease. Moreover, inadequate immunity 
significantly reduces the natural antitumor response. In order to 
avoid detrimental consequences that result from inappropriate 
immunological responses, directional migration of leukocytes in 
healthy individuals is a dynamic highly controlled process that is 
regulated by adhesion molecules and chemotactic cytokines or 
chemokines. Chemokines drive migration in a concentration- 
and site-dependent manner (13–18). The function and biological 
availability of chemokines and their receptors is modulated at 
multiple levels including transcription and translation (13). 
Concerning the dynamic process of chemokine regulation, it 
became more and more clear that also posttranslational modifica-
tions play an important role (19).
CHeMOKiNeS
Definition and Classification 
of Chemokines
Chemokines are small, chemotactic molecules with a molecular 
weight of about 7–12 kDa. They direct migration of leukocytes 
during inflammation as well as in homeostatic circumstances 
(13, 14, 16, 17). Rolling of leukocytes is followed by lose adhe-
sion of the cells to the endothelium (10). Selectins play an 
important role in generating primary adhesion interactions. 
Next, interaction of leukocytes with chemokines strengthens 
bonding between integrins on leukocytes and their counter-
receptors on endothelial cells, resulting in anchorage of 
leukocytes to the endothelium. In the end, a chemotactic 
gradient will act as a guide that navigates leukocytes to their 
final destinations (10, 20, 21).
Although, the mutual sequence homology of chemokines 
varies between less than 20% to over 90%, the tertiary struc-
ture of chemokines, in general, is quite similar (15–17). Most 
chemokines contain four cysteine residues that form disulfide 
bridges, which stabilize the tertiary structure of the protein. 
Chemokines contain a characteristic flexible NH2-terminal 
region of about 6–10 amino acids that is important for signal 
transduction. An NH2 terminal loop (N loop), that mouths into 
a 310-helix, is situated behind the flexible NH2-terminal region. 
The NH2-terminal residues and N loop contain determinants 
for binding of the chemokine to G protein-coupled receptors 
(GPCRs) and are followed by a three stranded β-sheet and a 
COOH-terminal helix (15). Classically, one distinguishes CXC, 
CC, C, and CX3C chemokines. The division into four subfamilies 
is based on the difference in localization of the two NH2-terminal 
cysteine residues and, consequently, is based on structural char-
acteristics (13, 16, 18).
Most CXC or α-chemokines are clustered on chromosome 
4q12–21 and contain only one random amino acid (X) between 
processing of these chemotactic proteins may have significant consequences for 
appropriate functioning of the immune system. After introducing the chemokine family 
together with the GPCRs and GAGs, as main interaction partners of chemokines, and 
discussing the different forms of posttranslational modifications, this review will focus on 
the intriguing relationship of chemokines with the serine protease CD26.
Keywords: chemokine, leukocyte migration, GPCR, glycosaminoglycan, posttranslational modification, 
proteolysis, dipeptidyl peptidase iv, CD26
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the two NH2-terminal cysteines (16). The human CXC subfam-
ily consists of 18 genes encoding 18 proteins (CXCL1 to 17 and 
CXCL4L1) that are further subdivided based on the presence 
or absence of a Glu-Leu-Arg (ELR) motif located just before 
the CXC motif. ELR+CXC chemokines, i.e., CXCL1 to CXCL3 
and CXCL5 to CXCL8, interact with CXC chemokine receptor 
(CXCR)1 and/or CXCR2, thereby mediating migration and 
activation of neutrophils. In general, members of this group of 
CXC chemokines also promote angiogenesis. This angiogenic 
activity partially explains why the pro-inflammatory CXCL8, 
or interleukin (IL)-8, has been associated with cancer (22, 
23). Moreover, it has been demonstrated that CXCL8 stimu-
lates migration of colorectal tumor cells in  vitro as well as 
in  vivo (24). Absence of the ELR motif, in contrast, implies 
completely different characteristics. The ELR negative (ELR−) 
CXC chemokines CXCL9 to CXCL11, for example, activate 
the receptor CXCR3 and mediate recruitment of T lympho-
cytes and NK cells (13). In contrast to the ELR+ relatives, the 
CXCR3 ligands have angiostatic properties. The first described 
chemokine ever, namely platelet factor-4 or CXCL4, is an 
ELR−CXC chemokine (25). CXCL4, released by activated blood 
platelets, is a weak CXCR3 ligand and chemoattractant for 
neutrophils, monocytes, and fibroblasts (26, 27). Due to its 
extremely high affinity for heparin, CXCL4 acts as a neutraliz-
ing agent for heparin-like molecules and hinders the thrombin 
inactivating capacity of these agents (28, 29). Moreover, it had 
been shown that CXCL4 inhibits endothelial cell proliferation, 
angiogenesis, and tumor growth (29–31). The highly related 
non-allelic variant of platelet factor-4, CXCL4L1, is an even 
better inhibitor of angiogenesis (32).
The second large subclass of human chemokines contains 
about 30 CC or β-chemokines. Individual members of this 
chemokine subfamily all contain an analogous CC motif and 
most CC chemokines are clustered on chromosome 17, sug-
gesting that the CC family arose as a result of gene duplication 
(13–16). CC or β-chemokines are subdivided into two main 
subgroups. One subfamily is the monocyte chemotactic proteins 
(MCPs) together with the eotaxins (33). These chemokines medi-
ate recruitment of, among others, monocytes, T lymphocytes, 
eosinophils, and basophils and promote histamine release by 
the latter. Consequently, they play an important role in inflam-
mation including allergic inflammation (34). Most other CC 
chemokines are considered as a separate CC chemokine subclass 
with high homology to the macrophage inflammatory proteins 
(MIP)-1α and MIP-1β (14).
In contrast to CXC and CC chemokines, C chemokines 
contain only two cysteines. Indeed, as a result, their overall 
topology is stabilized by only one disulfide bridge. Nowadays, 
XCL1 and XCL2, also known as lymphotactin α and β, respec-
tively, are the only C chemokines that have been identified 
(13–17). CX3CL1 – or fractalkine – is still the only CX3C 
chemokine that has been described. This chemokine not only 
acts as a chemoattractant but also plays a role as an adhesion 
molecule (35). Structurally, CX3CL1 contains an NH2-terminal 
chemokine domain, a long mucin-like domain of circa 110 
amino acids that is enriched for serine and threonine residues, 
a transmembrane domain, and a cytoplasmic tail. CX3CL1 is 
capable of anchoring to extracellular surfaces and is – together 
with the membrane-bound CXCL16 – an exception to the rule 
that chemokines are secreted proteins (15).
In addition to the structure-based classification of chemokines 
as CXC, CC, C, and CX3C family members, one respects a 
functional division between inflammatory and homeostatic 
chemokines (13, 15). Expression of inflammatory chemokines 
requires prior activation by stimuli that can be exogenous as 
well as endogenous. Examples of endogenous mediators that are 
potent inducers of expression of inflammatory chemokines are 
cytokines, for example, IFN-γ, tumor necrosis factor (TNF)-α, 
IL-1, IL-4, IL-5, IL-6, IL-13, and IL-17 (14, 15, 17, 18, 36, 37). 
Well known exogenous stimuli are microbial infection and viral 
and bacterial components such as the toll-like receptor ligands 
double stranded RNA, peptidoglycan, and lipopolysaccharide 
(14, 15, 18, 38, 39). The presence of pathogen-associated molecu-
lar patterns (PAMPs) on the surface of these factors facilitates 
recognition by the body, allowing generation of an appropriate 
immune response (1, 2). In fact, PAMPs on the surfaces of the 
infection-associated molecules interact with pattern recogniz-
ing receptors, enabling induction of chemokine production and 
subsequent leukocyte attraction (40). Examples of inflammatory 
CC chemokines are CCL2 and CCL5 (41).
Homeostatic chemokines control basal cell migration and are 
constitutively expressed. They enable correct hematopoiesis in 
bone marrow and thymus and direct migration of lymphocytes 
and dendritic cells to secondary lymphoid organs (15, 42, 43). 
Furthermore, homeostatic chemokines are responsible for leuko-
cyte migration in healthy peripheral tissues resulting in immune 
surveillance and maintenance of mucosal immunity (42–44). 
Genetic deficiency of CXCL13, for example, results in aberrances 
in the organization of Peyer’s patches in the intestine (44). In 
addition to the fact that homeostatic chemokines are necessary 
for correct functioning of the immune system, they do also play 
a role in various developmental processes (15, 42, 43). Migration 
through specific areas in secondary lymphoid organs during B 
and T lymphocyte development, for example, is navigated by 
homeostatic chemokines (42). Noteworthy, it is recommended 
to interpret the broad, function-based chemokine subdivision 
with some caution. The distinction between homeostatic and 
inflammatory chemokines is not absolute: some chemokines can 
fall into both categories, depending on the context (15, 45). On 
top of their role as leukocyte attractants, a number of chemokines 
(homeostatic and inflammatory) have also been reported to 
have direct chemokine receptor-independent antimicrobial 
activity [reviewed in Ref. (46)]. The direct antimicrobial activ-
ity in general requires higher concentrations compared to the 
concentrations needed to induce leukocyte migration (47, 48).
Chemokine Receptors
Chemokines exert their chemotactic activity via binding and 
activation of GPCRs. Since ligands of GPCRs are often non-
protein molecules and cytokines signal via non-GPCRs, the 
association between chemotactic cytokines and this type of 
receptors was not self-evident. The fact that neutrophils are char-
acterized by the presence of binding sites with a high affinity for 
CXCL8, together with the observation that Pertussis toxin is able 
FiGURe 1 | The chemokine family and effect of CD26 on chemokine receptor–ligand interactions. Various chemokines can be subjected to proteolytic 
processing by the enzyme dipeptidyl peptidase IV or CD26. The effects of truncation by CD26 are indicated by colors. Red, CD26-mediated proteolysis negatively 
affects the interaction between chemokine and chemokine receptor. Green, CD26-mediated proteolysis has a positive effect on the interaction between chemokine 
and chemokine receptor. Blue, proteolytic processing by CD26 does not influence the interaction between chemokine and chemokine receptor. Brown, the 
implications of truncation by CD26 remain to be determined. *, in contrast to intact CCL4, CCL4(3–69) shows affinity for CCR1 and CCR2. **, also known as 
CXCR7. ***, the notation “ACKR5” is reserved for this receptor. NC, not cleaved by CD26.
4
Metzemaekers et al. CD26–Chemokine Interactions
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 483
to block the effects of CXCL8, indicated that chemokine recep-
tors are GPCRs (49, 50). Indeed, Pertussis toxin is well known 
for its inactivating effect on the Gi type of G proteins. Nowadays, 
almost 20 chemokine receptors have been cloned within the 
over 600 human GPCRs. These GPCRs are known as CXCR1 
to CXCR6, CXCR8, CC chemokine receptor (CCR)1 to CCR10, 
CX3C chemokine receptor (CX3CR)1, and C chemokine receptor 
(XCR)1. They specifically interact with one or more chemokines 
of the corresponding subclass (19, 51–53) (Figure 1). CXCR2, 
for example, is capable of binding all seven known human 
ELR+CXC chemokines, whereas CXCR4 selectively interacts 
only with one chemokine, namely CXCL12. In addition, some 
chemokines activate multiple receptors. For example, CCL3L1 
and CCL5 show affinity for CCR1, CCR3, and CCR5 (54–56).
Interaction between a GPCR and a chemokine ligand results 
in receptor activation, followed by receptor-mediated signal 
transduction. GPCRs contain seven α-helices that cross the 
membrane. Individual transmembrane domains are mutually 
connected by three intracellular and three extracellular loops. 
The NH2-terminal region is located extracellularly, whereas the 
COOH-terminus faces the cytoplasm (15, 51). The extracellular 
loops and the NH2-terminal residues facilitate activation of a 
chemokine receptor, and the intracellular loops are crucial for 
coupling to G proteins (Figure 2). The second intracellular loop 
FiGURe 2 | Chemokine-induced signal transduction. Chemokine receptors are G protein-coupled receptors (GPCRs), implying that classical chemokine-
induced signaling is G protein-dependent. Binding of a chemokine ligand induces a change in conformation of the GPCR, thereby facilitating exchange of guanosine 
diphosphate (GDP), which is bound by the α-subunit of the G protein during receptor inactivity, for guanosine triphosphate (GTP). Most chemokine receptors are 
coupled to G proteins that hold an inhibitory type of α subunit (Gαi), implying that the newly formed Gα–GTP complex mediates inhibition of adenylyl cyclase, 
resulting in decreasing cyclic adenosine monophosphate (cAMP) concentrations. The βγ-subunit of the G protein (Gβγ), in turn, activates phospholipase Cβ (PLCβ), 
resulting in initiation of cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). The latter facilitates 
calcium release from the endoplasmic reticulum. Calcium and PIP2 cooperate in the activation of protein kinase C (PKC) and other calcium-sensitive protein kinases. 
In addition, Gβγ interacts with Ras, followed by activation of phosphatidylinositol-3-kinases (PI3K) and PIP3. PIP3 activates Rac, a GTPase, and interacts with protein 
kinase B (PKB), which are important for leukocyte migration and actin polymerization, respectively. In the end, modulation of actin-dependent processes regulates 
various leukocyte functions and initiates chemotaxis. In addition to G protein-dependent signaling, some chemokine receptors couple to arrestin after chemokine-
binding and phosphorylation of the receptor by G protein-coupled receptor kinases (GRK). Arrestin mediates G protein uncoupling of the receptor and plays a role in 
receptor desensitization. In addition, arrestin interaction can promote receptor internalization to endosomes and ligand degradation, initiation of an additional round 
of cell signaling, or receptor recycling to the cell membrane.
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contains a so called DRYLAIV-motif that is necessary to enable 
signal transduction (57, 58).
The G proteins are receptor-associated when the receptor is 
inactive. As long as the receptor is kept in its inactive confor-
mation, the guanosine triphosphatase (GTPase) domain of the 
α-subunit of the G protein is bound to guanosine diphosphate 
(GDP). However, binding of a suitable chemokine ligand gives 
rise to a conformational change in the receptor, thereby leading to 
the exchange of GDP for guanosine trisphosphate (GTP) (58–60). 
The newly formed Gα–GTP complex dissociates from the recep-
tor and from the βγ subunit of the G protein. With regard to α 
subunits, one respects a classification into Gαs, Gαi/Gαo, Gαq/
Gα11, and Gα12/Gα13 subtypes. These different subfamilies either 
stimulate or inactivate adenylylcyclases. Most chemokine recep-
tors are coupled to the Gαi subtype, which implies that binding of 
a chemokine ligand results in inhibition of adenylylcyclase, fol-
lowed by a decrease in concentration of the messenger molecule 
cyclic adenosine monophosphate (cAMP) Figure  2 (60). In 
addition, βγ subunits activate membrane-bound phospholipase 
C (PLC)β, which enables induction of cleavage of phosphati-
dylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) 
and inositol 1,4,5-trisphosphate (IP3). IP3, in turn, induces the 
release of calcium from the endoplasmic reticulum (ER) to the 
cytoplasm. DAG acts synergistically with calcium and activates 
various forms of protein kinase C (PKC) and other calcium-
sensitive protein kinases. The resulting cascade of protein 
phosphorylations ultimately leads to the generation of cellular 
effector responses. In addition to PIP2, the related phosphati-
dylinositol (3–5)-trisphosphate (PIP3), also plays an important 
role in chemokine receptor-induced signal transduction. This 
particular product of the phosphatidylinositol 3-kinase (PI3K) 
cascade activates Rac, a small GTPase that is indispensable for 
leukocyte migration. Furthermore, PIP3 contains an interaction 
site for protein kinase B (PKB). Interaction with this ligand is 
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important for actin polymerization (17). Modulation of actin-
dependent, cellular processes, in the end, gives rise to induction 
of chemotaxis and regulation of a variety of other functions in 
different types of leukocytes (15, 51).
In addition to classical G protein-dependent signaling, 
some chemokine receptors can couple to arrestin proteins 
Figure 2 (61–63). These adaptor proteins may bind the recep-
tor following agonist binding and receptor phosphorylation 
by G  protein-coupled receptor kinases (GRKs). By means 
of sterically hindering the phosphorylated receptor and its 
interaction with G  proteins, arrestin proteins uncouple the 
receptor from G  proteins and promote receptor desensitiza-
tion (64). Moreover, arrestin recruitment facilitates targeting 
of the receptor to clathrin-coated pits that are present at the 
cell surface (65, 66). As  a result, the receptor is internalized 
to endosomes and the ligand can be subjected to degradation. 
However, binding of arrestin does not necessarily promote 
receptor downregulation. Instead, in some cases, this interac-
tion initiates an additional round of signaling. Concerning 
the CXCL12/CXCR4 axis, for example, β arrestin-2 has been 
reported to enhance the activation of p38 mitogen-activated 
protein kinase (MAPK) and extracellular signal-regulated 
kinase (ERK) that is mediated by CXCR4 (67). In this way, 
β arrestin-2 plays an important role in CXCR4-mediated 
chemotaxis. In case a specific chemokine receptor interacts 
with multiple chemokine agonists, the impact of arrestin 
binding depends on the particular chemokine that binds to 
the receptor. For example, internalization of CCR7 following 
CCL19 binding is arrestin-dependent. However, this does not 
apply to the CCR7 ligand CCL21 (68). In addition to playing a 
role in chemokine receptor internalization and desensitization, 
ligand degradation, and initiation of an additional round of 
cell signaling, β-arrestin coupling can also mediate receptor 
recycling, resulting in constitutive trafficking of the receptor 
from intracellular vesicles to the cellular surface (69–72).
Furthermore, some of the identified chemokine receptors do 
not have the capacity to initiate classical signal transduction. 
These atypical chemokine receptors (ACKRs) have been associ-
ated with processes of internalization, degradation, neutraliza-
tion, and transport of chemokines (13, 69). ACKR1 to 4 and 
CCRL2 do not contain a complete DRYLAIV-motif and seem 
to play a role in regulation of chemokine availability (13, 73). 
ACKR1 binds both CC chemokines and CXC chemokines and 
promotes active transport of inflammatory chemokines from 
basolateral toward apical surfaces through endothelial cells 
(74, 75). As a consequence of the interaction with ACKR1, a 
chemokine ligand is internalized, resulting in stacking of the 
particular molecule on the apical side. Consequently, chemokine 
transcytosis that is realized by ACKR1 will result in increased 
leukocyte migration (75). ACKR1 is not only expressed by a 
variety of endothelial cells but can also be found on the surface 
of erythrocytes and epithelial cells (76–78). On erythrocytes, 
ACKR1 functions as a “sink” receptor (77, 79). This phenomenon 
facilitates maintenance of low chemokine concentrations in the 
blood in physiological circumstances, suggesting that the atypical 
chemokine receptor is important to keep particular chemokines 
in the circulation (19, 76).
Since the NH2-terminal chemokine domain is responsible 
for binding to GPCRs and activation of these receptors, this 
extremely flexible region is of high importance for a chemokine’s 
biological activity. The amino acids in front of the first cysteine 
residue are important for the receptor selectivity of the chemokine 
(79, 80). This NH2-terminal tail of chemokines interacts with 
a pocket in the transmembrane part of the receptors. Thus, it 
is not surprising that minor modification on the chemokine’s 
NH2-terminus may have a profound impact on the activity of 
these proteins (vide infra). In addition, a rigid loop that is located 
behind the second cysteine residue of the chemokine binds to the 
NH2-terminus of the receptors (81, 82). Accumulating evidence 
suggests an interplay between both interaction sites, which 
allows fine tuning of the selection and activation of signaling 
pathways (80).
For some chemokine receptors, three dimensional (3D) 
structures are already available. For example, crystal structures 
of CXCR4 in complex with several receptor antagonists have 
been mapped (83). Furthermore, the receptor was successfully 
crystalized in complex with a viral chemokine-like molecule 
(84). Recently, also improved insights into the 3D structure of 
CXCR1 were obtained using NMR-spectroscopy (85). Since 
exact structures of most chemokine receptors are still unknown, 
one frequently depends on hypothetical models that are based 
on bovine rhodopsin. This seven transmembrane protein is the 
prototype class A GPCR, and its 3D structure is completely 
determined. Class A GPCRs are important drug targets and, 
consequently, improving insights into the receptor structure 
facilitates the search for interaction partners with therapeutic 
applications. Given the central role of chemokines in leukocyte 
migration, modulation of receptor-ligand interactions in the con-
text of chemokines can be of potential value. Indeed, chemokines 
are associated with various pathological conditions such as acute 
and chronic inflammation (including autoimmune diseases) and 
cancer (41, 82, 86, 87).
Expression of chemokine receptors is strongly regulated 
and is not necessarily restricted to leukocytes (53). Certain 
conditions can give rise to ectopic expression on endothelial 
cells, epithelial cells, neurons, and microglial cells in the brain 
(88–92). Furthermore, expression of chemokine receptors is 
highly dynamic, as clearly illustrated by the expression patterns 
on T lymphocytes and dendritic cells. For T lymphocytes, a direct 
relation exists between the receptor expression pattern and the 
fact whether it is a naive or memory cell, whether the cell is 
activated or in an inactive state, and whether the cell has, e.g., 
a Th1 or a Th2 identity (93). For dendritic cells, the chemokine 
receptor expression pattern depends on the maturity of the cell 
(94). Strict regulation of receptor expression ensures correct 
positioning of lymphocytes and dendritic cells in peripheral or 
secondary lymphoid tissues.
Glycosaminoglycans
In addition to binding to GPCRs, chemokines interact with 
glycosaminoglycans (GAGs) with low affinity (13, 19). These 
long, linear, and heterogeneous sulfated polysaccharide chains 
are strongly negatively charged, making them attractive interac-
tion partners for chemokines, which are generally highly basic. 
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GAGs are present on the cellular surface and in the extracel-
lular matrix. They are usually found as part of a so-called 
proteoglycan structure in which multiple GAGs are bound to 
a protein core. Proteoglycans are associated with the cellular 
membrane and function as a macromolecular cell coating that 
is known as “glycocalyx.” The exact composition of GAGs is 
highly variable and depends on the location and cell type, 
by means of which some degree of selectivity for particular 
chemokines is ensured (95, 96). The differentiation status and 
the pathophysiological state seem to be important factors 
underlying this phenomenon (95, 97). Binding of chemokines 
to GAGs on the vascular endothelial surface, for example, 
provokes retention of chemokines, thereby enabling formation 
of a chemokine gradient, which is important for coordinated 
leukocyte migration. GAGs are also present at the surface of 
leukocytes (20). Here, loss of GAGs dramatically decreases the 
affinity of the cell for chemokines. Indeed, one presumes that 
the interaction between chemokines and GAGs influences the 
interaction between the chemokine ligands and their receptors 
(98). Chemokine binding to GAGs on the surface of leukocytes 
also has been reported to explain cooperativity between specific 
chemokines (99). By competition for binding to the same GAG 
on a leukocyte, one chemokine without a specific GPCR on 
that particular leukocyte (e.g., CXCL13) may detach the second 
chemokine (e.g., CCL19) from that GAG and allow this second 
chemokine to activate its specific GPCR (CCR7 in case of 
CCL19) with higher efficiency. In addition to these interactions 
with chemokines, GAGs can bind to a variety of other proteins. 
Thus, the finding that these heterogeneous macromolecules 
seem to be associated with many cell biological processes was 
not surprising (13, 95, 100).
The GAG chain structure is composed of a range of 1 up 
to 25,000 repeating hexose/hexuronic acid plus hexosamine 
units. These disaccharide building blocks are subjected to 
an extensive and variable degree of N- or O-sulfation and/
or C5 epimerization. Due to the exact composition, glycoside 
bond and degree of sulfation and acetylation, a strong variety 
between different disaccharide units is observed. In general, 
one discriminates heparan sulfate, heparin, chondroitin sul-
fate, keratan sulfate, dermatan sulfate, and hyaluronic acid. 
Excluding heparin and hyaluronic acid, GAGs are generally 
anchored to the cell membrane by means of proteoglycan 
structures (13, 95). Among the six different subclasses of GAGs, 
most of the existing knowledge and research concerns heparan 
sulfates and heparins. Heparan sulfates are expressed by almost 
all types of cells, making that heparan sulfate proteoglycans 
count for about 95% of all proteoglycans (101). The diversity 
between individual GAGs probably results from the fact that 
synthesis of GAG polymers is not based on a representative 
template (100). Instead, the production of GAGs depends on 
a range of complex enzymatic reactions (100).
The major GAG-binding domain of chemokines is often 
located in the COOH-terminal region and is physically separated 
from the receptor activation domain that is situated rather NH2-
terminally. The observation that these two important interac-
tion domains are localized apart from each other, gave rise to 
the hypothesis that chemokines can interact with both GAGs 
and GPCRs at the same time (100, 102). However, the GAG-
binding domain is not always restricted to the COOH-terminal 
region and overlaps partly with the receptor activation domain. 
Given the acidity that characterizes both chemokine receptors 
and GAGs, this is not surprising. Arginine, lysine, and – to a 
lesser extent – also histidine in the COOH-terminal α-helix of 
chemokines, turned out to be crucial hotspots for GAG binding 
(103–106). Most of the heparan sulfate-binding chemokines like 
CCL3, CCL4, and CCL5 have a “BBXB” GAG-binding consen-
sus motif in their 40s loop, where “B” symbolizes an arginine 
or a lysine residue (100, 103). Both are basic amino acids that 
facilitate binding of the chemokine to negatively charged GAGs. 
At the moment, the available knowledge on chemokine-binding 
sites on GAGs themselves is still limited (20, 100). For CXCL8, 
for example, it is only known that a minimum GAG length of 
18 monosaccharides is crucial. Ideally, a GAG chain contains 
two N-sulfated regions that both consist of six monosaccharides, 
which are separated from a region of maximum seven non-
sulfated disaccharide subunits (107).
Interaction with GAGs promotes oligomerization of 
chemokines. Indeed, in addition to monomers that are responsi-
ble for receptor activation, chemokines also occur as higher order 
aggregates (15). The capacity of GAGs to facilitate oligomeriza-
tion of chemokines was demonstrated in vitro for the first time 
for the chemokines CCL2, CCL3, CCL5, and CXCL8 (20). For 
example, the CC chemokine CCL2 can be subjected to dimeriza-
tion, and a dimer variant of the CXC chemokine CXCL8 has also 
been described (108, 109). Generation of CXCL dimers is based 
on formation of H-bridges between residues in the first strand 
of the β-sheets of two individual CXCL subunits (15). Indeed, 
combination of two CXCL subunits implies that, structurally, 
the resulting dimer is composed of a six stranded β-sheet. This 
β-sheet is stabilized by interactions between the COOH-terminal 
α-helices and the β-sheet of the two individual CXCL subunits. 
The topology of CCL dimers, in contrast, is remarkably less 
globular (15). These long and flexible structures arise when 
residues located in the NH2-terminal region of two CCL subunits 
interact, by means of which a two-stranded antiparallel β-sheet 
interface is formed (15, 108, 110). The positive effect of GAG 
binding on oligomerization is in line with the presumption that 
the negatively charged macromolecules facilitate highly specific 
and local increases in chemokine concentrations.
Binding of chemokines to GAGs and the resulting oli-
gomerization are important for leukocyte migration. This strictly 
regulated process is of crucial importance in pathophysiological 
circumstances as well as from a physiological point of view, and 
depends on the type of chemotactic molecule, both in vitro and 
in vivo (10). In vitro, it turned out that the process of chemo-
taxis not necessarily needs binding of chemokines to GAGs. 
Mutations in the GAG-binding domain of CCL2, CCL4, and 
CCL5, for example, do not affect the capacity of these chemokines 
to mediate generation of a chemotactic gradient in  vitro (111, 
112). In vivo chemotaxis mediated by these chemokines requires 
binding of chemokines to GAGs (111). Binding of chemokines 
to GAGs prevents diffusion of the ligand and probably has a 
protective function against proteolysis (113). Indeed, interfer-
ence with GAG binding by using short chemokine-derived 
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peptides, mutated chemokines without affinity for GPCRs, and 
enhanced-binding properties to GAGs, or chemokine-binding 
aptamers, which block chemokine–GAG interactions resulted 
in reduced leukocyte migration in vivo (114–116). In addition, 
in vivo heparin binding was shown to protect CCL11 (in)directly 
against proteolysis mediated by plasmin, cathepsin G, and elastin 
and positively affects the chemotactic activity of the chemokine 
(117). Evidence in favor of the hypothesis that GAG binding 
can serve as a protective factor regarding to proteolysis was also 
provided by the observation that binding to heparan sulfate or 
heparin oligosaccharides avoids CD26-mediated proteolysis of 
CXCL12 (118).
Posttranslational Modification
In a number of immunological processes, the importance of 
posttranslational protein modifications has been evidenced, 
e.g., glycosylation patterns play a major role in the generation 
of blood groups, proteolytic cleavage in the activation of IL-1β 
and IL-18, and citrullination in the generation of autoantigens 
during rheumatoid arthritis (119–122). For chemokines, the 
biological availability is not only coordinated at the level of 
gene expression but also depends on interactions with GAGs 
and atypical receptors. Moreover, the exact chemokine function 
is regulated in detail by the presence or absence of synergistic 
or antagonistic effects of other chemokines, alternative splic-
ing, and posttranslational modifications (13). Posttranslational 
modification of chemokines can result in an increase or a 
decrease of their biological activity and may affect their recep-
tor specificity. The importance of this phenomenon has been 
underestimated for a long time. However, since chemokine 
isoforms have been identified in vivo, the impact of posttrans-
lational modifications in the context of chemokine regulation 
receives higher recognition (19, 123, 124).
Proteolysis
Undoubtedly, the best known type of posttranslational modi-
fication on chemokines is proteolysis by specific enzymes (13, 
19). Both the NH2-terminal and the COOH-terminal end of a 
chemokine can be subjected to proteolysis and internal cleavage 
by endopeptidases has also been described (124).
NH2-Terminal Proteolysis
Important enzymes regarding truncation of the NH2-terminal 
region of a chemokine are matrix metalloproteases (MMPs), 
CD26, cathepsins, elastase, and proteinase-3 (125). CD13, plas-
min, and thrombin, which are present in plasma, can also medi-
ate proteolytic chemokine modification. MMPs are produced by 
stromal cells and leukocytes and hold several CC as well as CXC 
chemokines as substrates. NH2-terminal proteolysis of CXCL8 by 
MMP-9 for example, but also by thrombin or plasmin, generates 
CXCL8(6–77), CXCL8(7–77), and CXCL8(9–77) (126–128). In 
case of CXCL8, the truncated chemokine forms act as more 
potent stimulators of MMP-9 secretion and are more powerful 
mediators of neutrophil chemotaxis than the intact chemokine. 
Moreover, binding of NH2-terminally truncated CXCL8 to 
the receptor initiates enhanced mobilization of intracellular 
calcium compared to the uncleaved chemokine. Ultimately, the 
proteolytic cleavage leads to a 10- to 30-fold increase in capacity 
to activate neutrophils in vitro. A recent study demonstrated a 
role for MMP-2 and MMP-9 at the blood–brain barrier, where 
these proteases promote chemokine-induced migration of 
leukocytes (129). For CXCL8, over 10 naturally occurring NH2-
terminal forms have been described, most of these characterized 
by NH2-terminal truncation resulting in an increased biological 
activity (126, 130). In addition to ELR+CXC chemokines, such 
as CXCL8, several ELR−CXC chemokines are also MMP sub-
strates. MMP-8-, MMP-9-, or MMP-12-mediated proteolysis 
of CXCL11, for example, generates a chemokine form with 
decreased chemotactic activity and an increased ability to bind 
heparin (131). For CXCL12, several NH2-terminal forms have 
been found in human plasma, which are all characterized by 
decreased activity or even an antagonistic effect with respect to 
the uncleaved chemokine (132). Concerning CC chemokines, 
MCPs are well known substrates for MMPs and, here, proteolysis 
results in inactivity (133). MMPs do not only cleave chemokines 
but also promote degradation of the extracellular matrix (134, 
135). For some of these enzymes, increases in expression level 
are observed during conditions of inflammation and cancer 
(136–139). The role of cathepsins in posttranslational modifi-
cation of chemokines has been studied to a lesser extent. In a 
recent study, it was shown that the cysteine cathepsins K, L, and 
S, by means of NH2-terminal proteolysis, provoke activation 
and inactivation of several ELR+- and ELR−CXC chemokines, 
respectively (140). In this study, GAGs turned out to partly 
reduce the enzymatic process. The role of the serine protease 
CD26 in NH2-terminal chemokine modification will be dis-
cussed in detail in a separate paragraph.
COOH-Terminal Proteolysis
More recently, the COOH-terminal domain of certain chemokines 
has been proven to be sensitive to proteolysis by specific enzymes. 
As mentioned, the domain is often important for interactions 
with GAGs (vide supra). For most chemokines, loss of a small 
number of amino acids in the COOH-terminal region does not 
have a biological effect, but more drastic modifications may 
negatively affect interactions between chemokines and GAGs. 
Again, members of the MMP family play an important role. For 
example, MMP-8 facilitates degradation of CXCL9 and CXCL10, 
and the same applies to MMP-9 (141). Worth mentioning is the 
effect of MMPs on CXCL11. Although NH2-terminal cleavage 
results in generation of a molecule with antagonistic properties 
and enhanced binding to heparin (vide supra), COOH-terminal 
proteolysis leads to a loss of antagonistic properties and heparin 
binding (131). These findings underscore the importance of the 
COOH-terminal region with respect to GAG binding and sug-
gest that GAGs can modify the chemokine gradient in different 
directions. For CXCL12 – which is associated with lymphocyte 
migration and hematopoiesis – both termini can be subjected to 
proteolysis. Carboxypeptidase N-induced COOH-terminal pro-
teolysis of this chemokine significantly reduces the biological 
activity (142). The membrane-associated chemokines CXCL16 
and CX3CL1 can be subjected to proteolytic shedding as well. 
Furthermore, the intact membrane-associated form usually 
functions as an adhesion molecule and scavenger receptor, and 
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can be converted into a soluble form by “a disintegrin and metal-
loprotease” (ADAM)-10 and ADAM-17 (143–145). The soluble 
forms act as chemoattractants for different types of immune 
cells, such as activated T cells (146). Increased concentrations 
of the soluble form usually reflect inflammation (124, 147, 148).
Citrullination, Nitration, and Glycosylation
The posttranslational modification, which affects the chemokine 
mass the least, is peptidylarginine deiminase (PAD)-catalyzed 
deimination of arginine to the uncharged amino acid citrulline 
(124). Since citrullination reduces the number of positive charges 
on proteins, it can change their 3D structure, and this modifica-
tion has been reported to affect the interaction of proteins with 
lipids and GAGs (149–152). Furthermore, the sensitivity of a 
chemokine for proteolytic processing by serine proteases, which 
recognize positively charged residues can be affected (151). 
Protein citrullination and the presence of anti-citrullinated 
peptide antibodies have been linked to a number of specific 
pathological states including multiple sclerosis, rheumatoid 
arthritis, and psoriasis (121, 153–155). For chemokines, limited 
information is available on the importance of citrullination in a 
disease context. Increased concentrations of citrullinated CXCL5 
have been found in serum and synovial fluid of patients with 
rheumatoid arthritis and correlated with disease activity (156). 
Compared to the unmodified molecule, citrullinated CXCL5 
caused an enhanced monocyte but reduced neutrophil attrac-
tion in mice. In addition to citrullination of CXCL5, natural 
occurring citrullinated forms of CXCL8 and CXCL10 have been 
identified (151, 152). For CXCL8, citrullination was linked to 
protection of the chemokine against thrombin- and plasmin-
mediated proteolytic processing, reduced affinity for GAGs, 
and reduced in  vivo activity upon intraperitoneal injection in 
mice (151). Surprisingly, citrullination resulted in an increased 
capacity for CXCL8 to provoke mobilization of neutrophils 
into the blood circulation after intravenous injection in rabbits 
(157). Compared to the authentic chemokines, citrullinated 
forms of CXCL10 and CXCL11 were characterized by a dimin-
ished CXCR3 signaling capacity, impaired T cell chemotaxis, 
and reduced ability to bind to heparin (152). However, these 
citrullinated chemokines retained CXCR3 binding properties. 
Thus, although several natural citrullinated chemokines have 
been identified, their role in an in  vivo context, either for the 
regulation of leukocyte homeostasis or during inflammation 
remains unknown. A particular problem with this modification 
is the difficulty to detect specific citrullinated proteins with 
high sensitivity. Classical immunoassays do not discriminate 
between the unmodified and citrullinated forms, and the minor 
mass difference (one mass unit) renders identification by mass 
spectrometry extremely difficult, in particular in patient-derived 
body fluids such as serum or synovial fluids.
In vitro nitration by peroxynitrite has been described for the 
chemokines CCL2, CCL5, and CXCL12 (158). Peroxynitrite is a 
highly reactive ion that is generated in  vivo by the reaction of 
the free radicals superoxide and nitric oxide during sustained 
inflammation (159, 160). The unstable ion potently modifies 
several residues either directly (for methionine, tryptophan, and 
cysteine) or indirectly (for histidine, phenylalanine, and tyrosine) 
(161). The implications of nitration for chemokine function are 
divers. For CCL5, nitration was shown to significantly impair the 
potency of the chemokine to chemoattract eosinophils in vitro 
(162). Concerning CCL2, conflicting results have been reported. 
On the one hand, data were published, which claim that the 
ability of CCL2 to chemoattract antigen-specific CD8+ cells is 
reduced upon nitration, whereas the capacity of the chemokine 
to recruit CD14+ monocytes stays unaltered (163). On the other 
hand, nitration of CCL2 was linked to a reduction in monocyte 
chemotaxis (164). Recently, it was demonstrated for the first time 
that CXCL12 can be naturally nitrated on Tyr7 in an inflamed 
environment (165). Compared to unmodified CXCL12, the capac-
ity of this novel and naturally occurring nitrated CXCL12 form 
to provoke intracellular calcium release was impaired. Nitration 
reduced the ability of CXCL12 to chemoattract monocytes and 
lymphocytes in  vitro and, more importantly, nitrated CXCL12 
was not longer able to recruit lymphocytes to the joints in vivo.
Last, some chemokines can be subjected to N- or O-glycosylation. 
The in vivo importance of this phenomenon is still to be eluci-
dated. For example, the functional stability of CCL2 improves 
after O-glycosylation, but the in vitro chemotactic activity of the 
glycosylated molecule is not significantly altered (166, 167). In 
line with this observation, the in vitro chemotactic activities of 
CCL5 and CCL11 are also not influenced by glycosylation (168, 
169). The limited availability of purified natural glycoforms of 
human chemokines and the difficulty to produce recombinant 
chemokines that contain specific sugar chains identical to the 
natural human sugars hampers profound investigation through 
in vivo studies.
DiPePTiDYL PePTiDASe iv/CD26
Molecular Characteristics, Structure, and 
Signal Transduction
Dipeptidyl peptidase (DPP) IV was described for the first time by 
Hopsu-Havu and Glenner in 1966 as an active enzyme in livers 
of rats (170, 171). The serine protease is also named “adenosine 
complexing protein 2” or “cluster of differentiation 26” (CD26) 
and, nowadays, is considered to be the most important member 
of the DPP family (172). The family, strictly speaking, consists 
of four prolyl-specific peptidases, i.e., DPPIV/CD26, fibroblast-
activating protein-α (FAP-α), DPP8, and DPP9, but, based on 
substrate specificity and structural homology, prolyl endopepti-
dase (PREP) or prolyl oligopeptidase (POP), DPPII, and prolyl 
carboxypeptidase (PRCP) are sometimes considered as family 
members as well. The DPP enzymes have been associated with 
a broad spectrum of physiological and pathophysiological pro-
cesses of the immune system. In this review, we will specifically 
focus on CD26 in a chemokine context. The complex immuno-
logical roles of the activity and/or structural homologs of CD26 
were recently reviewed by Wagner et al. (173).
The human CD26 gene contains 26 exons and is located on 
chromosome 2q.24.3. The gene spans a region of circa 70  kb 
(174). Flanking to the 5′ end, a sequence of 300 base pairs is 
located that consists for not less than 72% of cytosine and guanine 
residues, implying that the sequence holds potential-binding sites 
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for growth factors such as the nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) and hepatocyte nuclear 
transcription factor 1 (HNF-1). Absence of a TATA box and a 
high CG content, which characterize the CD26 gene, are typical 
features of a promotor region of a house keeping gene (175). The 
coding glycoprotein, as a monomer, has a size of 110 kDa and is 
multifunctional. CD26 exists both as a soluble molecule as well as 
in a membrane-bound form and functions as a serine protease, as 
a receptor, as an adhesion molecule for collagen and fibronectin, 
as a costimulatory signal for T lymphocytes, and is involved in 
apoptosis (176). Conditions of hypoxia promote CD26 expression 
and hypoxia-inducible protein-1α (HIP-1α) is a strong inducing 
factor for CD26 gene expression and protein production. Several 
cytokines including IFNs and IL-1β, retinoic acid, and HNF-1 can 
also stimulate activation of CD26 on fibroblasts, epithelial cells, 
endothelial cells, and leukocytes (177–180).
Membrane-bound CD26 contains a transmembrane domain 
that is located 28 residues from the NH2-terminus and is a 
leukocyte surface marker (176, 181, 182). The protein shows 
catalytic proteolytic activity only as a dimer and can be found 
on the surface of T and B cells, NK cells, some types of 
macrophages, and hematopoietic stem and progenitor cells. In 
addition, fibroblasts, endothelial, acinar, and epithelial cells of 
different tissues like kidney and liver do also express CD26. 
Both termini of the protein contribute to the formation of a 
so called β-propeller domain (amino acids 55–497) (Figure 3). 
The β-propeller structure holds seven sheets and contains only 
hydrophobic bonds and salt bridges, implying that the region 
is extremely flexible. Furthermore, the protein contains an 
α/β hydroxylase domain (amino acid 39–51 and amino acid 
506–766) that is covalently bound to the β-propeller domain. 
All together, these properties imply that the catalytic pocket 
is situated in a locked hole. The other side of the β-propeller 
domain faces the extracellular environment. It cannot be 
excluded that the flexibility of the β-propeller domain plays a 
role in facilitating the passage of substrates toward the catalytic 
pocket of CD26. However, only entrance of substrates through a 
side opening of the enzyme is supported by experimental data at 
the moment (183–185). In addition to functional homodimeric 
CD26, active heterodimers with FAPα have also been described 
(183).
CD26 contains multiple regions that can be subjected to 
N-glycosylation. Research, however, suggests that glycosylation 
of these sequences does not have implications for dimerization 
of the protein, binding to adenosine deaminase (ADA), or the 
catalytic activity (186). Residues in the catalytic pocket are 
highly conserved, and the presence of only point mutations is 
already sufficient to inhibit enzymatic functioning of CD26. 
The sequence at the height of the catalytic serine is G-W-S-Y-G 
implying that the protein meets the typical serine protease 
consensus motif, namely G-x-S-x-G (176, 182). Concerning its 
function as a serine protease, CD26 is highly specific: the pro-
tease cleaves NH2-terminal dipeptide sequences of proteins, only 
if a (hydroxy)proline or an alanine is present in the penultimate 
NH2-terminal position. The signal transduction cascade that is 
initiated by CD26 is not completely determined at the moment, 
but is, anyhow, associated with mobilization of intracellular 
calcium and partly involves the same substrates as those involved 
in T cell receptor-induced signal transduction, like stimulation of 
MAPK and PLCγ activity (182).
In addition to the membrane-bound protein, a soluble form 
of CD26 can be found in serum and in various body fluids, for 
example in seminal fluid (182). Soluble CD26 or sCD26 is – prob-
ably by means of proteolysis – derived from the membrane-bound 
form and has a stimulating effect on the proliferation of activated 
lymphocytes in peripheral blood. It has been demonstrated that 
MMP1, MMP2, MMP9, and MMP14 are able to facilitate release 
of soluble CD26 from adipocytes and vascular smooth muscle 
cells (187). The structures of sCD26 and membrane-bound CD26 
are highly similar, the only difference being the absence of the 
cytoplasmic domains and the transmembrane domain for sCD26 
(182). Like membrane-bound CD26, sCD26 is characterized by 
strong glycosylation. The degree of glycosylation increases with 
increasing age and some types of hypersialylation can inhibit 
CD26 activity (188). In addition to CD26, other circulating 
molecules with a similar activity exist. DPPII, for example, also 
cleaves the two NH2-terminal amino acids from substrates with 
a proline or an alanine residue in the penultimate NH2-terminal 
position (189, 190). Moreover, the activity of membrane-bound 
CD26 and sCD26 are possibly regulated by circulating attractin 
(189). Changes in sCD26 concentration and, in general, in CD26 
activity, have been associated with a variety of pathophysiological 
conditions. Decreases in activity have been related to immune 
suppressive conditions and several tumor types. Reduced sCD26 
concentrations, on the one hand, have been found in patients 
with systemic lupus erythromatosus, among others (191). 
Inflammatory and infectious conditions, liver diseases, and 
other types of tumors, on the other hand, are associated with 
increased CD26 activity and enhanced sCD26 levels. Increased 
CD26 expression as found in patients with T cell lymphoma or 
B cell leukemia, for example, is positively correlated to disease 
aggressiveness (192, 193).
Functions
CD26 as Receptor, Costimulator, and Adhesion 
Molecule and Its Relation with Apoptosis
As a receptor, CD26 can interact with either receptor- or non-
receptor molecules. Undoubtedly, the most reported binding 
partner of membrane-bound CD26 is ADA, an enzyme that 
catalyzes the irreversible conversion of adenosine and 2′-deoxy-
adenosine into, respectively, inosine and 2′-deoxyinosine and 
which plays a role in the development and functioning of lym-
phoid tissues (176, 194). Adenosine and 2-deoxyadenosine, in 
fact, have negative effects on the activation of both T and B cells. 
The direct association between ADA and CD26 ensures local 
degradation of adenosine and induces T cell proliferation. The 
ADA–CD26 complex is of importance in regulation of adhesion 
of T lymphocytes to epithelial cells. The interaction between the 
two enzymes, furthermore, functions as a costimulatory signal 
for T cell activation (195). Here, the signal transduction through 
CD26 is directly related to its expression level on T lymphocytes 
(196). Last, in the immunological synapse, interaction between 
the ADA–CD26 complex on T cells and ADA receptors on 
dendritic cells mediates increased release of pro-inflammatory 
FiGURe 3 | Schematic structure of homodimeric CD26. Each CD26 monomer consists of an intracellular NH2-terminal tail, a transmembrane region, a flexible 
part, a glycosylation-rich region, a cysteine-rich region, and a catalytic domain. Ser630, Asp708, and His740 are involved in the catalytic process and are generally 
referred to as “the catalytic triad.” Structurally, the two termini of a CD26 monomer contribute to the formation of a β-propeller structure. An α/β-hydroxylase domain 
is covalently bound to the β-propeller structure. These structural features imply that CD26’s catalytic pocket is situated in a locked hole.
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cytokines such as IFN-γ, TNF-α, and IL-6 (197). Another enzyme 
that can be bound by CD26 is the zymogen plasminogen (198). 
Interaction with CD26 realizes its conversion to active plasmin. 
Plasmin promotes degradation of the extracellular matrix and, 
in this way, is involved in cell migration, tumor invasion, and 
metastasis.
The glycosylation domain of CD26 contains mannose 6-phos-
phate (M6P) residues that can interact with the M6P/insulin-like 
growth factor II-receptor (IGFIIR) (199). The complex formation 
results in internalization of CD26 and enables recycling of CD26 
in hepatocytes and intestinal epithelial cells. Furthermore, this 
interaction with IGFIIR is required with respect to the function of 
CD26 as a costimulatory signal in T cell proliferation. The second 
receptor that can be subjected to interaction with CD26 is CXCR4 
(200). This chemokine receptor selectively binds CXCL12 and 
binding of the latter to the CXCR4–CD26 complex provokes 
internalization of both receptors. In this way, the CXCR4–CD26 
complex probably regulates the local activity of CXCL12, and 
CD26 seems to exert a direct influence on the antiviral activity 
of CXCL12, its hematopoietic effects, and its functionality as a 
chemoattractant (200–202).
A high content of Gly-Pro sequences makes collagen a 
potential CD26 interaction partner. In 1988, it became clear 
that CD26, as expected, facilitates the spreading of hepatocytes 
in  vitro and enhances binding of the cells to natural collagen 
in vitro (203). The domain that is responsible for these inter-
actions is situated in the cysteine-rich region of the enzyme. 
By means of interacting with the extracellular matrix proteins 
collagen and fibronectin, CD26 is involved in processes of cell 
adhesion and migration (204). Disruption of the adhesion-
promoting functions of CD26 has been associated with 
various pathophysiological conditions. For example, cultured 
hepatoma cells show decreased membrane expression of CD26 
protein, increased sCD26 levels, and loss of adhesion (205). 
Furthermore, the protein functions as a collagen receptor in the 
activation of CD4+ lymphocytes (206).
The influence of the multifunctional CD26 protein on 
apoptosis probably depends on the context and the particular 
cell type involved (176). In several liver cell lines, for example, 
CD26 is physically associated with a tyrosine kinase and pos-
sesses apoptosis-promoting properties (207). On the other hand, 
parental Jurkat T cells that are CD26 negative or that are trans-
fected with mutant CD26, show increased expression of the cell 
death-associated Fas receptor CD95 and, compared to the CD26 
positive parenteral Jurkat T cells, are more prone to be subjected 
to apoptosis (208).
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Enzymatic Activity of CD26
The serine protease CD26 typically shows a strong selectivity 
for short chain peptides whose penultimate position in the 
NH2-terminal amino acid sequence is occupied by a (hydroxy)
proline or an alanine residue (176, 209). Substrate binding and 
catalysis are realized by the catalytic pocket, with the rate of the 
proteolytic process being inversely related to the chain length of 
the substrate. The substrate selectivity of the enzyme is reflected 
by the kcat/KM ratio. Here, kcat and KM, respectively, represent the 
catalytic- and the Michaëlis–Menten constant, and the mutual 
ratio reflects the selectivity constant. The latter can be used 
as a measure for the half-life of a substrate at a fixed enzyme 
concentration. Notation of positions of residues relatively to the 
scissile bond is in accordance with the classification system of 
Schechter and Berger that dates from 1968 (210). Amino acids in 
the direction of the NH2-terminus are represented by P1, P2, etc. 
and residues in the direction of the COOH-terminus are referred 
to as P  P1′ ′, 2 , etc. CD26 shows a strong selectivity for substrates 
with a (hydroxy)proline or an alanine in the P1 position and is 
stereo specific: the scissile bond and the bond between P1 and 
P2 have to be in trans configuration (211).
CD26 and Chemokines
The relationship between CD26 and the immune system 
extends beyond expression of the membrane-bound enzyme on 
immune-related cells such as B and T lymphocytes. Indeed, many 
chemokines hold a proline or an alanine residue in the penulti-
mate position of their NH2-terminal sequence. Presence of this 
motif, which is strongly preferred by CD26, suggests that the 
chemotactic proteins are sensitive to proteolysis by the enzyme. 
Based on in vitro as well as in vivo research, several chemokines 
have been identified as CD26 substrates (Table 1) (13, 19, 123, 
124, 212–214). As mentioned before, the NH2-terminal domain 
determines the capacity of chemokines to activate GPCRs. 
Therefore, it is not surprising that limited proteolysis within this 
region can affect the interaction between chemokines and their 
receptors (Figure 1). The effect of enzymatic cleavage turned out 
to be highly complex and, depending on the chemokine and the 
type of truncation, can result in either an increase or a decrease in 
the biological activity, can alter the chemokine’s receptor prefer-
ence, or generate receptor antagonists. The fact that chemokines 
are involved in a broad range of crucial cellular processes in 
pathological as well as physiological conditions underlines the 
potential implications of CD26-mediated proteolysis in the 
context of chemokines.
CC Chemokines
Based on in vitro and in vivo experiments, several CC chemokines 
were identified as CD26 substrates. Although the three human 
MCPs have an NH2-terminal penultimate Pro, the presence 
of a pyroglutamic acid – which results from cyclization of an 
NH2-terminal glutaminyl precursor molecule – in all three mol-
ecules (CCL2, CCL7, and CCL8) protects these natural human 
chemokines from cleavage by CD26 (236). However, when MCPs 
are produced in bacteria as recombinant proteins, they have an 
NH2-terminal glutamine instead of a pyroglutamic acid and 
become artificial CD26 substrates. Upon storage at neutral or 
slightly basic pH conditions, the glutamine in the recombinant 
chemokines will spontaneously convert into a pyroglutamic 
acid. Interestingly, for human and murine CCL2, the enzyme 
responsible for NH2-terminal cyclization into pyroglutamic acid 
was demonstrated to be the isoenzyme of glutaminyl cyclase 
(237). Moreover, inhibition of this enzyme by using small orally 
available molecules reduced the monocyte filtration induced by 
murine CCL2 in an in vivo atherosclerosis model. These observa-
tions support the idea that interfering with chemokine cleavage 
is of potential clinical value.
Most of the CD26-truncated human CC chemokine forms 
were successfully isolated from natural resources [(Table 1) (I)]. 
An individual CC chemokine usually activates multiple receptors 
and NH2-terminal proteolysis, in most cases, implies a change 
in receptor preference. Truncated CC chemokines might show 
increased affinity for a specific receptor or, in contrast, a reduced 
affinity or missing activity, resulting in receptor inhibition. 
Indeed, in this way, proteolysis induced by CD26 often interferes 
with the chemotactic properties of these chemokines.
CCL3L1 and CCL3
A clear pro-inflammatory effect of CD26-mediated proteolysis 
was demonstrated for the first time for the chemokine CCL3L1. 
Indeed, the truncated form CCL3L1(3–70) shows increased affin-
ity for CCR1 (54). Consequently, the pro-inflammatory proper-
ties of the chemokine, together with the chemotactic activity for 
monocytes, are enhanced. In addition to being an outstanding 
CCR1 agonist, the affinity of the truncated chemokine for CCR5 
remains very strong and, as a consequence, the modified CCL3L1 
form owns potent anti-HIV-1 activity. Noteworthy, it was recently 
shown that CD26-mediated proteolytic processing of the murine 
CCL3, which is more related to human CCL3L1 than to human 
CCL3 due to a proline residue in the penultimate NH2-terminal 
position, results in loss of myelosuppressive activity in vitro (202). 
Moreover, the truncated form acts as an inhibitor with respect 
to the myelosuppressive activity of the corresponding full length 
chemokine. These data were confirmed in mice. However, as it 
was demonstrated that the myelosuppressive activity of CCL3 
was not mediated through CCR1 or CCR5, the two known recep-
tors for CCL3, it remains to be elucidated via which receptor 
CCL3 manifests this myelosuppression (202, 238).
CCL4
The β chemokine CCL4, together with CCL3, is released by 
T  lymphocytes and monocytes (216). The intact chemokine 
shows a selective CCR5 affinity and holds, by means of receptor 
occupation and receptor downregulation, anti-HIV-1 activity. 
CCR5 is expressed by macrophages and lymphocytes, implying 
that CCL4 directs migration of these CCR5 positive cells toward 
lymph nodes or other tissues. CCL4(3–69) is secreted by activated 
T lymphocytes, shows preserved effects on CCR5 and, moreover, 
acquires affinity for CCR1 and CCR2 (215, 216, 239). The change 
in receptor specificity that characterizes CCL4(3–69) suggests that 
the truncated CCL4 form plays a role in chemotaxis and migration 
of CCR1 and CCR2 positive cells, such as monocytes, immature 
dendritic cells, and lymphocytes. It has been demonstrated that 
TABLe 1 | Overview of the chemokines that have been identified as CD26 substrates.
Chemokine Amino acids in the 
truncated form
Type of 
research
Original source of cleaved chemokine Biological effect Reference
(i) CC chemokines
CCL3L1 3–70a In vivo, indirect Mononuclear cells of peripheral blood Increased on CCR1 and CCR5; 
decreased on CCR3
(19, 54, 55, 
189)
CCL4 3–69a In vivo, indirect Activated peripheral lymphocytes Increased on CCR1 and CCR2, 
unchanged on CCR5
(19, 189, 215, 
216)
CCL5 3–68a In vitro, indirect Cytokine-stimulated fibroblasts, sarcoma cells,  
and leukocytes
Decreased on CCR1 and CCR3, 
increased on CCR5
(19, 56, 189, 
217–220)
CCL11 3–74a In vitro; in vivo 
in rats
Dermal fibroblasts Decreased activity on CCR3, inhibitor 
of intact CCL11
(19, 169, 189, 
221–223)
CCL22 3–69a In vitro Transformed CD8+ T lymphocytes Decreased on CCR4, monocyte 
chemotaxis unaffected
(19, 189, 224, 
225)5–69
(ii) CXC chemokines
CXCL2 3–73 In vitro – Unknown (19)
CXCL6 3–77a In vitro Cytokine-stimulated MG-63 osteosarcoma cells Preserved effect on neutrophils (19, 189, 226)
CXCL9 3–103 In vitro – Inactivity, decreased effect on T cells (19, 189, 227)
CXCL10 3–77a In vivo, indirect Cytokine-stimulated fibroblasts and MG-63 
osteosarcoma cells
Inactivity, decreased effect on T cells, 
and CXCR3 inhibition
(19, 180, 189, 
226–228)In vivo in mice
CXCL11 3–73a In vivo IFN-γ-stimulated keratinocytes Inactivity, decreased effect on T cells, 
and CXCR3 inhibition
(19, 189, 227, 
229–231)
CXCL12α 3–68 In vivo, indirect Blood plasma (human, mouse, and rhesus  
monkey) in physiological conditions
Inactivity, decreased effect on 
lymphocytes, CXCR4 inhibition
(19, 133, 189, 
232–235)
CXCL12β 3–72a In vivo, indirect Can be found in blood plasma from human, mouse, 
and rhesus monkey in physiological conditions
Unknown (19, 133, 189, 
234)
Several CC and CXC chemokines were identified as potential CD26 substrates. For many of these chemokines, the NH2-terminal truncated form was successfully isolated from 
natural resources (a) and the effect of CD26-mediated proteolysis on receptor selectivity and biological activity was examined. “Indirect” refers to a lack of in vivo or in vitro studies 
with inhibitors. Studies that are mentioned following the heading “type of research” are human studies unless indicated differently.
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CCL4(3–69), in contrast to intact CCL4, no longer enhances pro-
liferation of single cytokine-sensitive hematopoietic progenitor 
cells in vitro (202). Moreover, the truncated CCL4 form inhibits 
the enhancing activity of the intact chemokine.
CCL5
In the context of CD26-mediated proteolytic processing of CC 
chemokines, CCL5 was the first chemokine that was examined 
in detail. The chemokine promotes recruitment of, among others, 
monocytes, eosinophils, basophils, and NK cells via activation 
of three different receptors. The NH2-terminally truncated form 
CCL5(3–68) was successfully isolated from natural sources 
including conditioned media of fibroblasts, sarcoma cells, and 
leukocytes and shows a deviating receptor selectivity compared to 
the intact chemokine (56, 217). CCL5(3–68) is a more powerful 
activator of CCR5, but has lost affinity for CCR1 and CCR3 (56, 
218). The modified chemokine is still chemotactic for lympho-
cytes, but no longer owns the capacity to chemoattract monocytes 
and eosinophils, and, moreover, acts as an inhibitor with respect 
to chemotaxis induced by CCL5(1–68), CCL3, CCL4, and CCL7. 
In addition to a function as a chemokine receptor, CCR5 acts as 
an important co-receptor for the human immunodeficiency virus 
(HIV). Consequently, CCL5 competes with the virus for binding 
to the receptor. Since the affinity of CD26-truncated CCL5 for 
the CCR5 receptor is remarkably higher, CCL5(3–68) has been 
found to be an extremely potent HIV-1 inhibitor (219, 220).
CCL11
As suggested by its original name – being eotaxin – CCL11 is an 
important chemoattractant for eosinophilic granulocytes. These 
cells facilitate defense against multicellular parasites and are 
involved in the mechanisms that underlie allergic asthma. The 
truncated isoform CCL11(3–74) has lost affinity for CCR3 and, 
consequently, no longer holds chemotactic activity for eosinophils 
(222). In an in vivo study, it was demonstrated that CD26-deficient 
rats and wild-type animals that were treated with a CD26 inhibi-
tor, characteristically show enhanced mobilization of eosinophils 
compared to wild-type animals (221). These findings imply a 
potential role for CD26 as regulator of eosinophil recruitment.
CCL22
CCL22 is secreted by macrophages and dendritic cells. The 
chemokine interacts with CCR4 and facilitates chemotaxis of 
activated T lymphocytes, monocytes, NK cells, and dendritic 
cells. The capacity to activate CCR4 decreases following prote-
olysis by CD26 and, consequently, also the capacity of CCL22 
to direct lymphocyte chemotaxis is lost (240). CCL22(3–69) 
has preserved monocyte chemotactic properties and, moreover, 
shows increased anti-HIV-1 activity compared to the intact 
chemokine form (224, 225, 240). CCR4, at the moment, is the 
only receptor for CCL22 that has been identified, but is currently 
not described to be a co-receptor for HIV-1. For this reason, the 
increased antiviral capacity of CCL22 is highly remarkable and 
suggests existence of an additional CCL22 receptor (225). In vitro, 
CD26 has been shown to facilitate the unexpected proteolytic 
conversion of CCL22(3–69) into CCL22(5–69) (240). This is 
remarkable given that the protease, which generally shows strong 
selectivity for dipeptides with a (hydroxy)proline or an alanine 
in the penultimate NH2-terminal position, in this case, cleaves 
behind a Tyr-Gly dipeptide.
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CXC Chemokines
ELR+CXC Chemokines
ELR+CXC chemokines activate CXCR1 and/or CXCR2 and 
facilitate chemotaxis of neutrophils. In general, they are angio-
genic. NH2-terminal proteolysis has direct consequences for the 
receptor affinity and biological activity of almost all ELR+CXC 
chemokines including CXCL8 (vide supra). Most ELR+CXC 
chemokines, with the exception of CXCL2 and CXCL6, are no 
CD26 substrates because they do not possess a penultimate NH2-
terminal proline or alanine. Knowledge concerning the role of 
CD26 in posttranslational modification of CXCL2 and CXCL6 
is limited. CD26 cleaves CXCL2 and also CXCL6 in vitro (241). 
Natural human CXCL6(3–77), isolated from stimulated osteosar-
coma cells, does not show a significantly altered in vitro chemo-
tactic activity compared to the intact form on neutrophils (219, 
226). Noteworthy, the mouse chemokine CXCL1 – in contrast to 
human CXCL1 – contains a proline residue in the penultimate 
position, implying that the chemokine is also a potential substrate 
for CD26 (242).
ELR−CXC Chemokines
The three interferon-induced ELR−CXC chemokines, i.e., 
CXCL9, CXCL10, and CXCL11, interact with CXCR3 and induce 
chemotaxis of activated T lymphocytes and NK cells (243). Most 
ELR−CXC chemokines, with exception of CXCL12 and CXCL16, 
are angiostatic. NH2-terminal truncated forms of the CXCR3 
agonists CXCL9, CXCL10, and CXCL11 show preserved antian-
giogenic properties but their capacity to trigger CXCR3-mediated 
signal transduction is limited (227). As a consequence, the capac-
ity of the truncated chemokine forms to provoke lymphocyte 
chemotaxis is significantly reduced. Recently, it was shown that 
CXCL9, following proteolytic processing by CD26, no longer acts 
as a myelosuppressive protein in vitro and in vivo (202). Instead, 
the truncated form counteracts the myelosuppressive effects of 
the corresponding intact chemokine.
Among the CXCR3 agonists, CD26-mediated proteolysis of 
CXCL11, in particular, turned out to be highly efficient with 
half-lives of the chemokines in the range of minutes in the 
presence of physiological concentrations of sCD26. The resulting 
CXCL11(3–73), as well as the CXCL10 form CXCL10(3–77), 
were isolated from natural sources (180, 229). Moreover, proteo-
lytic processing of CXCL10 by CD26 was demonstrated in mice 
(228). Higher concentrations of intact CXCL10 were found in 
mice that were treated with the CD26 inhibitor sitagliptin com-
pared to animals that did not receive the inhibitor. In contrast 
to sitagliptin-treated mice, untreated animals showed reduced 
infiltration of leukocytes into tumor tissue and a significantly 
decreased natural antitumor immunity. This is in line with former 
data that indicate that the truncated form CXCL10(3–77) is 
biologically inactive (227). Recently, based on two prospective 
clinical trials, it was confirmed that, in human, CD26 cleaves 
CXCL10 in  vivo (244). This study for the first time provided 
direct in vivo evidence in favor of inhibition of CD26 in human 
to preserve intact CXCL10 by means of protecting the chemokine 
against proteolytic processing by CD26, which generates biologi-
cally inactive CXCL10(3–77). Noteworthy, biologically inactive 
CXCL10(3–77) was previously found in plasma from patients 
that suffer from a chronic viral hepatitis C infection (245).
CXCL12α acts as a strong chemoattractant for lymphocytes 
and CD34+ hematopoietic progenitor cells (246). Through inter-
action with CXCR4, together with CCR5 the most important 
co-receptor for HIV-1, this chemokine exerts potent antiviral 
activity. NH2-terminal proteolysis of this CD26 substrate nega-
tively affects its capacity to bind CXCR4, which is reflected in 
a significantly reduced chemotactic- and antiviral activity of 
CXCL12α(3–68) compared to the intact chemokine (232). For 
this reason, the relationship between CD26 and HIV-1 seems 
to be dual: while CCL5(3–68) is characterized by increased 
anti-HIV-1 activity (vide supra) through enhanced interaction 
with CCR5, CXCL12α(3–68) is a less potent inhibitor of the 
virus compared to intact CXCL12α due to reduced affinity for 
CXCR4. Directly in line with the former results that suggest 
that CXCL12α(3–68) is biologically inactive, it was shown that 
CXCL12-mediated homing of hematopoietic progenitor cells 
in vivo is enhanced in Cd26−/− mice and wild-type animals that 
received the CD26 inhibitor diprotin A, compared to untreated 
wild-type animals (247). The CD26 inhibitor protects CXCL12 
from inactivation, resulting in enhanced cell migration, which 
is reflected in increased efficiency of cell homing after bone 
marrow transplantation. Noteworthy, an earlier study revealed 
that CD26 not only negatively affects the capacity of CXCL12 
to mediate progenitor cell survival but also acts as a more 
general negative regulator of colony-stimulating factor activity 
and stress hematopoiesis through cleavage of growth factors 
and cytokines including granulocyte-macrophage colony-
stimulating factor, granulocyte colony-stimulating factor, 
erythropoietin, and IL-3 (248, 249). In line with the obser-
vations from animal studies, it was found that inhibition of 
CD26 enhances clinical cord blood transplantation in humans 
with hematological malignancies (250, 251). Furthermore, the 
CD26–CXCR4 axis seems to play an important role in oncol-
ogy. Cancer cells derived from patients with Sézary syndrome, 
for example, typically show absence of membrane-bound CD26 
and increased expression of CXCR4 and CXCL12 (252). As 
a consequence, the chemokine is no longer inactivated, and 
the neoplastic cells show outstanding migratory properties. 
The latter process can be strongly reduced by administration 
of sCD26.
inhibition of CD26
Relevance and Implications
It becomes more and more evident that the multifunctional serine 
protease CD26 is associated with a variety of pathophysiological 
and physiological processes. In addition to chemokines, a broad 
range of regulatory peptides, mainly those involved in glucose 
metabolism, have been identified as substrates for this peptidase 
(189). For this reason, a range of different inhibitors are already 
used in vitro and in vivo and some inhibitors have been approved 
for treatment of diabetes patients. The principle of inhibition is 
always based on interaction of these molecules with the catalytic 
region of CD26, but further characteristics of specific inhibitors 
are highly diverse. For example, the inhibitor–enzyme interaction 
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can be reversible or irreversible, an inhibitor can be a product 
analog as well as a substrate analog, inhibition can be competitive 
or non-competitive, etc.
In Europe and the United States, the reversible and competi-
tive inhibitors sitagliptin, saxagliptin, vildagliptin, alogliptin, 
and linagliptin are already available on the market for thera-
peutic use (209, 253, 254). With regard to older studies that 
are based on the use of CD26 inhibitors, it is recommended 
to interpret the evidence of the results with some caution. A 
number of the CD26 inhibitors that have been used in these 
studies turned out to inhibit DPP8 and DPP9 as well, suggesting 
that the observed effects may not be attributed to inhibition of 
CD26 only (255).
CD26 Inhibitors
For some regulators of glucose homeostasis and insulin secre-
tion, it has been confirmed that these molecules are sensitive 
to NH2-terminal proteolysis by CD26. Glucose-dependent 
insulinotrophic polypeptide (GIP) and gastrointestinal hormone 
glucagon-like peptide 1 (GLP-1), among others, are proteolyti-
cally processed by CD26 in vitro as well as in vivo (256). GLP-1 
is postprandially secreted by L cells in the small intestine and 
colon and stimulates both in vitro and in vivo insulin secretion. 
Cleavage of the NH2-terminal region generates biologically 
inactive des(His-Ala)-GLP-1. In addition, CD26-mediated 
truncation of GIP results in inactivity as well. Ultimately, genera-
tion of the two antagonists leads to the development of insulin 
resistance. Accordingly, the therapeutic benefit for diabetic 
patients that are treated with CD26 inhibitors, is not surprising 
(257). The role of CD26 in regulation of neuropeptide activity 
falls beyond the scope of this review; however, it is worth men-
tioning that also CD26-mediated processing of neuropeptide 
Y, for example, affects its receptor preference (258, 259). Thus, 
it became clear that CD26-provoked NH2-terminal truncation 
affects the function of multiple peptide families with physiologi-
cal consequences on glucose metabolism, immunological, and 
neurological responses.
In 2006, the first in class CD26 inhibitor sitagliptin became 
available on the market for use as an oral anti-hyperglycemicum. 
The drug is a selective and competitive inhibitor that binds CD26 
non-covalently and in a reversible manner (260). Inhibition of the 
serine protease, mediated by sitagliptin, rests on the principle of 
structure–activity relationships.
Here, interaction with sitagliptin negatively affects the 
relationship between the structure and the biological activity of 
CD26. More specifically, a hydrogen bond is formed between the 
drug and amino acid Tyr547 of CD26. As a result, the residue is 
no longer able to facilitate stabilization of the active pocket of 
the enzyme.
Use of CD26 inhibitors, such as sitagliptin, is considered as 
a recent and revolutionary approach in the treatment of type 
2 diabetes. The underlying mechanism rests on prevention of 
proteolytic cleavage of GIP and GLP-1, by means of which 
insulin secretion and β cell proliferation are facilitated on 
the one hand and, on the other hand, glucagon secretion and 
apoptosis are inhibited (261). As a drug, a very favorable safety 
profile characterizes sitagliptin. The inhibitor, in general, is well 
tolerated and the adverse effects that have been described are 
only mild or moderate and of low incidence (262). Sitagliptin is 
excreted unchanged for over 80% by means of renal excretion 
and is subjected to metabolism to a limited extent only. The latter 
process is realized by the cytochrome P450 enzymes CYP3A4 
and CYP2C6 and the metabolites that are formed are completely 
inactive (263, 264).
In addition to sitagliptin, the CD26 inhibitors saxagliptin, 
vildagliptin, alogliptin, and linagliptin are approved for thera-
peutic purposes in Europe and the United States (254). However, 
sitagliptin and alogliptin are considered to be the only inhibitors 
that selectively inhibit CD26 and no other related peptidases. 
Excluding linagliptin, which is almost completely bound to pro-
teins when in circulation, inhibitors generally show only limited 
and reversible protein binding (265, 266). As a consequence, 
linagliptin is primarily hepatically cleared. This is in direct 
contrast with other inhibitors that are primarily renally excreted. 
Among the five approved inhibitors, vildagliptin is the only one 
that needs to be dosed twice a day instead of once daily. Moreover, 
vildagliptin is associated with an increase in hepatic enzymes 
and, consequently, is not recommended in patients with mild to 
moderate hepatic insufficiency.
The wide range of potential CD26 substrates, together 
with the fact that CD26 has been associated with a variety of 
pathological processes, support the idea that the serine protease 
is an interesting drug target and suggest a broader scope of 
application for use of CD26 inhibitors [reviewed in detail in Ref. 
(267)]. Concerning chemokines, it was recently demonstrated 
that sitagliptin-treated mice, following intravenous stimulation 
with CpG, show increased concentrations of intact CXCL10 
and increased antitumor activity compared to animals that did 
not receive the CD26 inhibitor (228). Moreover, it had been 
shown that sitagliptin in vivo blocks CD26-mediated truncation 
of CXCL10 in human (244).
CONCLUDiNG ReMARKS
Since the identification of chemokine isoforms both in vitro and 
in vivo, the role of posttranslational modifications of chemokines 
in the regulation of the biological activity of these chemotactic 
proteins can no longer be neglected. Over the years, it became 
clear that many chemokines can be subjected to proteolytic 
processing by the serine protease DPP IV or CD26. The enzyme 
cleaves the two most NH2-terminal residues from substrates 
with a proline or alanine in the penultimate position. The NH2-
terminal domain of chemokines is crucial for their interaction 
with chemokine receptors and, consequently, CD26-mediated 
proteolysis can have significant implications for the receptor 
specificity and the chemotactic activity of chemokines. Indeed, 
chemokines are crucial for correct leukocyte migration in patho-
physiological as well as homeostatic conditions and, therefore, 
they are essential for proper functioning of the immune system. 
Consistently, proteolytic processing by CD26 potentially has 
major effects on the organism’s well-being. Results from in vivo 
studies in mice with CD26 inhibitors provide evidence for this 
hypothesis. More research concerning the role of CD26-mediated 
chemokine processing in  vivo in human will be necessary; 
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however, the existing data support the idea that the enzyme 
plays a significant role in chemokine modification and that 
CD26-inhibitors are of potential therapeutic value in treatment 
of a variety of pathological conditions. In-depth epidemiological 
analysis of the progression of inflammatory diseases in diabetes 
patients who have been treated with CD26 inhibitors during the 
last decade will be an important step to unravel the role of CD26 
in chemokine-mediated inflammatory processes.
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